



NATIONAL QUALITY FORUM

Driving measurable health
improvements together

Memo

August 8, 2022

To: NQF members
From: NQF staff
Re: Renal Spring 2022 Measure Review Cycle

Background

This report reflects the review of measures in the Renal project. Measures in this portfolio target the complexity of renal care to improve diagnosis, treatment, and management of conditions. The measures in this review cycle focus on several clinical areas, including standardized fistula rates, standardized modality switch ratio for incident dialysis patients, first year standardized waitlist ratio, percentage of prevalent patients waitlisted in active status, and optimal end-stage renal disease starts.

The Renal [Standing Committee](#) reviewed six measures. Two measures were recommended for endorsement, but the remaining four were not recommended for endorsement.

Recommended Measures:

- NQF #2594 Optimal End-Stage Renal Disease (ESRD) Starts (The Permanente Foundation/Kaiser Permanente Southern California)
- NQF #3695 Percentage of Prevalent Patients Waitlisted (PPPW) (Centers for Medicare & Medicaid Services [CMS]/University of Michigan Kidney and Epidemiology Cost Center [UM-KECC])

Measures Not Recommended:

- NQF #3659 Standardized Fistula Rate for Incident Patients (CMS/UM-KECC)
- NQF #3689 First Year Standardized Waitlist Ratio (FYSWR) (CMS/UM-KECC)
- NQF #3694 Percentage of Prevalent Patients Waitlisted in Active Status (aPPPW) (CMS/UM-KECC)
- NQF #3696 Standardized Modality Switch Ratio for Incident Dialysis Patients (SMoSR) (CMS/UM-KECC)

The Standing Committee requests comments on all measures.

NQF Member and Public Commenting

NQF members and the public are encouraged to provide comments via the online commenting tool on the draft report as a whole or on the specific measures evaluated by the Renal Standing Committee.

Please note that commenting concludes on September 6, 2022, at 11:59 PM ET—no exceptions.

<https://www.qualityforum.org>